Minimal clinically important differences for treatment of hallucinations in Parkinson's disease and dementia with Lewy bodies.

ABSTRACT:

Background

Hallucinations are common and distressing symptoms in Parkinson's disease (PD). Treatment response in clinical trials is measured using validated questionnaires, including the Scale for Assessment of Positive Symptoms-Hallucinations (SAPS-H) and University of Miami PD Hallucinations Questionnaire (UM-PDHQ). The minimum clinically important difference (MCID) has not been determined for either scale. This study aimed to estimate a range of MCIDs for SAPS-H and UM-PDHQ using both consensus-based and statistical approaches.

Methods

A Delphi survey was used to seek opinions of researchers, clinicians, and people with lived experience. We defined consensus as agreement ≥75%. Statistical approaches used blinded data from the first 100 PD participants in the Trial for Ond

SUBMITTER: Reeves S 

PROVIDER: S-EPMC12080632 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature